Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-168.38M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -31.26% |
| Return on Assets (Trailing 12 Months) | -29.27% |
| Current Ratio (Most Recent Fiscal Quarter) | 19.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 19.94 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.80 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.40 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.65 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 85.58M |
| Free Float | 70.09M |
| Market Capitalization | $252.46M |
| Average Volume (Last 20 Days) | 0.41M |
| Beta (Past 60 Months) | 0.17 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 18.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.67% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |